A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of HS-10518 in Healthy Adult Premenopausal Females in China
Latest Information Update: 09 Nov 2023
At a glance
- Drugs Merigolix (Primary)
- Indications Endometriosis
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
Most Recent Events
- 09 Nov 2023 New trial record